WO2014122621A3 - Compositions and methods for the treatment of metabolic conditions and neuromuscular diseases - Google Patents

Compositions and methods for the treatment of metabolic conditions and neuromuscular diseases Download PDF

Info

Publication number
WO2014122621A3
WO2014122621A3 PCT/IB2014/058869 IB2014058869W WO2014122621A3 WO 2014122621 A3 WO2014122621 A3 WO 2014122621A3 IB 2014058869 W IB2014058869 W IB 2014058869W WO 2014122621 A3 WO2014122621 A3 WO 2014122621A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compositions
treatment
methods
metabolic conditions
Prior art date
Application number
PCT/IB2014/058869
Other languages
French (fr)
Other versions
WO2014122621A2 (en
Inventor
Mahesh Kandula
Original Assignee
Cellixbio Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellixbio Private Limited filed Critical Cellixbio Private Limited
Publication of WO2014122621A2 publication Critical patent/WO2014122621A2/en
Publication of WO2014122621A3 publication Critical patent/WO2014122621A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing metabolic conditions and neuromuscular diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of myopathy, muscular diseases, metabolism related genetic disorders.
PCT/IB2014/058869 2013-02-09 2014-02-08 Compositions and methods for the treatment of metabolic conditions and neuromuscular diseases WO2014122621A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN551CH2013 2013-02-09
IN551/CHE/2013 2013-02-09

Publications (2)

Publication Number Publication Date
WO2014122621A2 WO2014122621A2 (en) 2014-08-14
WO2014122621A3 true WO2014122621A3 (en) 2017-03-23

Family

ID=51300222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/058869 WO2014122621A2 (en) 2013-02-09 2014-02-08 Compositions and methods for the treatment of metabolic conditions and neuromuscular diseases

Country Status (1)

Country Link
WO (1) WO2014122621A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240148751A1 (en) * 2022-10-13 2024-05-09 Hong Kong Baptist University Identification of oleanolic acid and plant extract for glucose-6-phosphate dehydrogenase-related disorders including Bag3opathy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013014565A1 (en) * 2011-07-27 2013-01-31 Mahesh Kandula Compositions and methods for the treatment of metabolic conditions and muscular disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013014565A1 (en) * 2011-07-27 2013-01-31 Mahesh Kandula Compositions and methods for the treatment of metabolic conditions and muscular disorders

Also Published As

Publication number Publication date
WO2014122621A2 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
MX347616B (en) Csf-1r inhibitors for treatment of brain tumors.
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2014102592A3 (en) Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
MX2022005523A (en) Compositions and methods for the treatment of fungal infections.
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
IN2014KN01113A (en)
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
WO2014122621A3 (en) Compositions and methods for the treatment of metabolic conditions and neuromuscular diseases
MX2019005568A (en) Compositions and methods for the treatment of gastrointestinal polyps.
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2014068459A3 (en) Compositions and methods for the treatment of pain and neurological diseases
WO2013167984A3 (en) Compositions and methods for the treatment of muscle pain

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14748588

Country of ref document: EP

Kind code of ref document: A2